Abstract:OBJECTIVE:This study was designed to examine the impact of the antioxidant metallothionein (MT) on cardiac contractile, intracellular Ca(2+) function and oxidative stress in lipopolysaccharide (LPS)-treated mice.METHODS:Weight and age matched adult male FVB and cardiac-specific MT-overexpressing transgenic mice were injected intraperitoneally with 4 mg/kg Escherichia Coli LPS dissolved in sterile saline or an equivalent volume of pathogen-free saline (control groups). Six hours following LPS or saline injection, cardiac geometry and function were evaluated in anesthetized mice using the 2-D guided M-mode echocardiography. Mechanical and intracellular Ca(2+) properties were examined in hearts. Cell shortening and relengthening were assessed using the following indices: peak shortening (PS)-indicative of the amplitude a cell can shorten during contraction; maximal velocities of cell shortening and relengthening (± dl/dt)-indicative of peak ventricular contractility; time-to-PS (TPS)-indicative of systolic duration; time-to-90% relengthening (TR(90))-indicative of diastolic duration (90% rather 100% relengthening was used to avoid noisy signal at baseline concentration). The 360 nm excitation scan was repeated at the end of the protocol and qualitative changes in intracellular Ca(2+) concentration were inferred from the ratio of fura-2 fluorescence intensity (FFI) at two wavelengths (360/380). Fluorescence decay time was measured as an indicator of the intracellular Ca(2+) clearing rate. Glutathione/glutathione disulfide ratio and ROS generation were detected as the markers of oxidative stress.RESULTS:Heart rate was increased while EF was reduced in LPS-FVB mice and heart rate was reduced and EF increased in MT-LPS transgenic mice [(528 ± 72) beats/min vs (557 ± 69) beats/min, (66 ± 14)% vs (42 ± 10)%, P < 0.05]. Cardiomyocytes from the LPS treated FVB mice displayed significantly reduced peak shortening (PS) and maximal velocity of shortening/relengthening (±dl/dt) associated with prolonged time-to-90% relengthening (TR(90)), these effects were attenuated in cardiomyocytes from the MT-LPS mice [PS(5 ± 1.1)% vs (7.2 ± 0.8)%, dl/dt(160 ± 15) µm/s vs (212 ± 36) µm/s, -dl/dt (175 ± 32) µm/s vs (208 ± 29) µm/s, TR(90) (0.24 ± 0.03)s vs (0.19 ± 0.02)s, P < 0.05]. LPS treated mice showed significantly reduced peak intracellular Ca(2+) and electrically-stimulated rise in intracellular Ca(2+) as well as prolonged intracellular Ca(2+) decay rate without affecting the basal intracellular Ca(2+) levels, again, these effects were significantly attenuated in MT-LPS transgenic mice. Metallothionein overexpression also ablated oxidative stress [reduced ROS generation and increased glutathione/glutathione disulfide ratio, ROS (0.35 ± 0.08) A/µg protein vs (0.24 ± 0.03) A/µg protein]. GSH/GSSG 2.1 ± 0.2 vs 2.6 ± 0.4, P < 0.05.CONCLUSION:MT overexpression improved cardiac function and ablated oxidative stress in LPS treated mice.

Metallothionein alleviates cardiac contractile dysfunction induced by insulin resistance: role of Akt phosphorylation, PTB1B, PPARγ and c- Jun

Metallothionein Antagonizes Aging-Induced Cardiac Contractile Dysfunction: Role of Ptp1b, Insulin Receptor Tyrosine Phosphorylation and Akt

Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: role of oxidative stress, protein carbonyl formation and insulin sensitivity

Metallothionein Prevents High-Fat Diet-Induced Cardiac Contractile Dysfunction - Role Of Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha And Mitochondrial Biogenesis

Metallothionein Prevents High-Fat Diet–Induced Cardiac Contractile Dysfunction

Metallothionein Alleviates Cardiac Dysfunction in Streptozotocin-Induced Diabetes: Role of Ca2+ Cycling Proteins, NADPH Oxidase, Poly(adp-Ribose) Polymerase and Myosin Heavy Chain Isozyme

Sex Difference In Cardiomyocyte Function In Normal And Metallothionein Transgenic Mice: The Effect Of Diabetes Mellitus

Abstract 486: Genetic Deletion of Akt2 and AMPK Accentuates Insulin Resistance-Induced Cardiac Contractile Anomalies

CARDIAC OVEREXPRESSION OF METALLOTHIONEIN RESCUES CHRONIC ALCOHOL INTAKE-INDUCED CARDIOMYOCYTE DYSFUNCTION: ROLE OF AKT, MAMMALIAN TARGET OF RAPAMYCIN AND RIBOSOMAL P70S6 KINASE

Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury.

Antioxidant Metallothionein Alleviates Endoplasmic Reticulum Stress-Induced Myocardial Apoptosis and Contractile Dysfunction

Inhibition Of Superoxide Generation And Associated Nitrosative Damage Is Involved In Metallothionein Prevention Of Diabetic Cardiomyopathy

Macrophage Migration Inhibitory Factor Deficiency Augments Cardiac Dysfunction in Type 1 Diabetic Murine Cardiomyocytes

Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection.

Heavy Metal Scavenger Metallothionein Attenuates ER Stress-Induced Myocardial Contractile Anomalies: Role of Autophagy

Cardiac Metallothionein Overexpression Improves Cardiac Contractile Function and Attenuates Oxidative Stress in Lipopolysaccharide-Treated Mice

Metallothionein Prevents Intermittent Hypoxia-Induced Cardiac Endoplasmic Reticulum Stress and Cell Death Likely Via Activation of Akt Signaling Pathway in Mice.

Metallothionein Prolongs Survival and Antagonizes Senescence-Associated Cardiomyocyte Diastolic Dysfunction: Role of Oxidative Stress.

Cardiac Overexpression of Metallothionein Rescues Cold Exposure-Induced Myocardial Contractile Dysfunction Through Attenuation of Cardiac Fibrosis Despite Cardiomyocyte Mechanical Anomalies

Cardiac-specific overexpression of metallothionein attenuates L-NAME-induced myocardial contractile anomalies and apoptosis

Metallothionein Prevents Diabetes-Induced Deficits in Cardiomyocytes by Inhibiting Reactive Oxygen Species Production.